Genovis AB (publ.) (STO:GENO)

Market Cap	1.26B -28.5%
Revenue (ttm)	142.12M +14.3%
Net Income	20.50M -24.0%
EPS	0.31 -24.8%
Shares Out	66.06M
PE Ratio	61.43
Forward PE	37.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,344
Open	19.00
Previous Close	19.02
Day's Range	19.00 - 20.25
52-Week Range	15.64 - 29.00
Beta	1.75
Analysts	Strong Buy
Price Target	33.00 (+66.0%)
Earnings Date	Jul 23, 2026

About Genovis AB (publ.)

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisRE...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 36
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: GENO

Financial Performance

In 2025, Genovis AB (publ.)'s revenue was 129.93 million, a decrease of -1.06% compared to the previous year's 131.32 million. Earnings were 23.50 million, a decrease of -28.61%.

Analyst Summary

According to 2 analysts, the average rating for GENO stock is "Strong Buy." The 12-month stock price target is kr 33.00, which is an increase of 66.00% from the latest price.

Price Target

kr 33.00

(66.00% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 24, 2026

Data Sources Report a data error